Torrent Pharmaceuticals

Torrent Pharmaceuticals

TORNTPHARM.NSApproved
Ahmedabad, IndiaFounded 1959torrentpharma.com

Torrent Pharmaceuticals Limited is a prominent Indian multinational pharmaceutical company founded in 1959, known for its focus on branded generics and specialty pharmaceuticals. The company has a diversified portfolio spanning cardiovascular, CNS, gastro-intestinal, and anti-diabetic segments, with operations in over 40 countries. Torrent has established itself as a quality manufacturer with multiple FDA-approved facilities and continues to invest in R&D for complex generics and novel drug delivery systems.

Market Cap
$15.4B
Founded
1959
Employees
8,000-10,000
Focus
Biotech

TORNTPHARM.NS · Stock Price

USD 4272.90+2923.62 (+216.68%)

Historical price data

AI Company Overview

Torrent Pharmaceuticals Limited is a prominent Indian multinational pharmaceutical company founded in 1959, known for its focus on branded generics and specialty pharmaceuticals. The company has a diversified portfolio spanning cardiovascular, CNS, gastro-intestinal, and anti-diabetic segments, with operations in over 40 countries. Torrent has established itself as a quality manufacturer with multiple FDA-approved facilities and continues to invest in R&D for complex generics and novel drug delivery systems.

Technology Platform

Torrent focuses on branded generics with expertise in complex formulations, modified-release drug delivery systems, and fixed-dose combinations across multiple therapeutic areas.

Pipeline Snapshot

72

72 drugs in pipeline, 3 in Phase 3

DrugIndicationStageWatch
Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd) + ACZONE® (dapsone) gel, 7.5% (Al...Acne VulgarisPhase 3
TRC041266 + PlaceboChronic Stable Heart FailurePhase 3
TRC150094 + PlaceboDiabetesPhase 3
TRC150094Metabolic Cardiovascular SyndromePhase 1/2
Torrent's Isosorbide Mononitrate 120 mg ER TabletsHealthyPhase 1

FDA Approved Drugs

72
FIDAXOMICINANDAJan 27, 2026
LAMOTRIGINEANDAJan 8, 2026
NILOTINIB HYDROCHLORIDEANDADec 15, 2025

Opportunities

Torrent is well-positioned to capitalize on India's growing pharmaceutical market, expand its international presence in regulated markets, and develop complex generics and biosimilars.
The company's strong therapeutic focus areas offer significant growth potential.

Risk Factors

Key risks include intense competition in generic markets, regulatory compliance challenges across multiple jurisdictions, currency fluctuation exposure, and potential patent litigation risks in competitive therapeutic areas.

Competitive Landscape

Torrent competes with major Indian pharma companies like Sun Pharma, Dr. Reddy's, and Cipla, differentiating itself through branded generics focus, therapeutic expertise, and quality manufacturing. The company's international presence provides competitive advantages in diversified markets.

Publications
20
Patents
20
Pipeline
72
FDA Approvals
72

Company Info

TypeTherapeutics
Founded1959
Employees8,000-10,000
LocationAhmedabad, India
StageApproved
RevenueRevenue Generating

Trading

TickerTORNTPHARM.NS
ExchangeNSE

Therapeutic Areas

CardiovascularCentral Nervous SystemGastro-intestinalDiabetologyPain Management

Partners

Various international distribution partnersContract manufacturing partners
SIMILAR COMPANIES
Mankind Pharma
Mankind Pharma
Pre-clinical · New Delhi
Sun Pharmaceutical
Sun Pharmaceutical
Pre-clinical ·
Lupin Limited
Lupin Limited
Pre-clinical ·
Aurobindo Pharma
Aurobindo Pharma
Pre-clinical · Hyderabad
Dr. Reddy's Laboratories
Dr. Reddy's Laboratories
Pre-clinical · Princeton
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile